{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:56:38Z","timestamp":1790819798240,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/deed.de"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00347-026-02465-1","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:48:59Z","timestamp":1783496939000},"page":"770-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wegweisende Studien in der Augenheilkunde\u00a0\u2013 von der klinischen Studie zur Leitlinientherapie","Pioneering trials in ophthalmology\u2014From clinical trials to guideline treatment"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3086-6425","authenticated-orcid":false,"given":"Immanuel Philipp","family":"Seitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2465_CR1","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen\u00a0AM, Ricci\u00a0F, Paris\u00a0LP et\u00a0al (2021) Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a\u00a0review of preclinical data. Eye 35:1305\u20131316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x","journal-title":"Eye (Lond)"},{"key":"2465_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier\u00a0JS, Khanani\u00a0AM, Ruiz C\u00a0Q et\u00a0al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/s0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"2465_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong\u00a0TY, Haskova\u00a0Z, Asik\u00a0K et\u00a0al (2024) Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmol Sci 131:708\u2013723. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026","journal-title":"Ophthalmology"},{"key":"2465_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"LO Hattenbach","year":"2023","unstructured":"Hattenbach\u00a0LO, Abreu\u00a0F, Arrisi\u00a0P et\u00a0al (2023) BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. Ophthalmol Sci 3:100302. https:\/\/doi.org\/10.1016\/j.xops.2023.100302","journal-title":"Ophthalmol Sci"},{"key":"2465_CR5","unstructured":"DOG (2022) Erg\u00e4nzende Stellungnahme zu den IVOM-Medikamenten zur Therapie des diabetischen Makula\u00f6dems mit fovealer Beteiligung, DOG und BVA."},{"key":"2465_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jval.2017.04.006","volume":"20","author":"VD Lauenroth","year":"2017","unstructured":"Lauenroth\u00a0VD, Stargardt\u00a0T (2017) Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG? Value Health 20:927\u2013935. https:\/\/doi.org\/10.1016\/j.jval.2017.04.006","journal-title":"Value in Health"},{"key":"2465_CR7","unstructured":"DOG R, BVA (2022) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augen\u00e4rzte DeutschlandsAnti-VEGF-Therapie bei der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration."},{"key":"2465_CR8","unstructured":"AWMF (2025) Spezielle Diagnostik und Therapie von Netzhautkomplikationen bei Diabetes."},{"key":"2465_CR9","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41433-020-0842-z","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma\u00a0A, Parachuri\u00a0N, Kumar\u00a0N et\u00a0al (2020) Brolucizumab-key learnings from HAWK and HARRIER. Eye 34:1318\u20131320. https:\/\/doi.org\/10.1038\/s41433-020-0842-z","journal-title":"Eye (Lond)"},{"key":"2465_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel\u00a0PU, Koh\u00a0A, Ogura\u00a0Y et\u00a0al (2020) HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci 127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"2465_CR11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","volume":"402","author":"JS Heier","year":"2023","unstructured":"Heier\u00a0JS, Lad\u00a0EM, Holz\u00a0FG et\u00a0al (2023) Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. The Lancet 402:1434\u20131448. https:\/\/doi.org\/10.1016\/S0140-6736(23)01520-9","journal-title":"The Lancet"},{"key":"2465_CR12","unstructured":"EMA (2024) Syfovre : EPAR - Refusal public assessment report, EMA\/CHMP\/196327\/2025 Corr."},{"key":"2465_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ajo.2024.02.021","volume":"263","author":"KG Csaky","year":"2024","unstructured":"Csaky\u00a0KG, Miller\u00a0JML, Martin\u00a0DF et\u00a0al (2024) Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go. AJO Int 263:231\u2013239. https:\/\/doi.org\/10.1016\/j.ajo.2024.02.021","journal-title":"Am J Ophthalmol"},{"key":"2465_CR14","unstructured":"EMA (2024) Questions and answers on the refusal of the marketing authorisation for Syfovre (pegcetacoplan), EMA\/432931\/2024."},{"key":"2465_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell\u00a0S, Bennett\u00a0J, Wellman\u00a0JA et\u00a0al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849\u2013860. https:\/\/doi.org\/10.1016\/s0140-6736(17)31868-8","journal-title":"Lancet"},{"key":"2465_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/ceo.13022","volume":"46","author":"DC Chung","year":"2018","unstructured":"Chung\u00a0DC, McCague\u00a0S, Yu\u00a0ZF et\u00a0al (2018) Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol 46:247\u2013259. https:\/\/doi.org\/10.1111\/ceo.13022","journal-title":"Clin Exp Ophthalmol"},{"key":"2465_CR17","unstructured":"EMA (2018) Assessment report: Luxturna, Procedure No. EMEA\/H\/C\/004451\/0000."},{"key":"2465_CR18","unstructured":"G\u2011BA (2019) Nutzenbewertungsverfahren zum Wirkstoff Voretigen Neparvovec, 2019-04-15-D-436. Gemeinsamer Bundesausschuss."},{"key":"2465_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-021-00311-0","volume":"14","author":"V Ronco","year":"2021","unstructured":"Ronco\u00a0V, Dilecce\u00a0M, Lanati\u00a0E et\u00a0al (2021) Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? J\u00a0Pharm Policy Pract 14:30. https:\/\/doi.org\/10.1186\/s40545-021-00311-0","journal-title":"J Pharm Policy Pract"},{"key":"2465_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2025-002326","volume":"10","author":"LT Phan","year":"2025","unstructured":"Phan\u00a0LT, Hong\u00a0T, Chang\u00a0JH et\u00a0al (2025) A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study. BMJ Open Ophthalmology 10:e002326. https:\/\/doi.org\/10.1136\/bmjophth-2025-002326","journal-title":"BMJ Open Ophthalmology"},{"key":"2465_CR21","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.14.46","volume":"65","author":"KL Huber","year":"2024","unstructured":"Huber\u00a0KL, Stino\u00a0H, Steiner\u00a0I et\u00a0al (2024) Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema. Invest Ophthalmol Vis Sci 65:46. https:\/\/doi.org\/10.1167\/iovs.65.14.46","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2465_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren\u00a0RE, Groppe\u00a0M, Barnard\u00a0AR et\u00a0al (2014) Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. The Lancet 383:1129\u20131137. https:\/\/doi.org\/10.1016\/S0140-6736(13)62117-0","journal-title":"The Lancet"},{"key":"2465_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaophthalmol.2020.1032","volume":"138","author":"MD Fischer","year":"2020","unstructured":"Fischer\u00a0MD, Michalakis\u00a0S, Wilhelm\u00a0B et\u00a0al (2020) Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A\u00a0Nonrandomized Controlled Trial. JAMA Ophthalmol 138:643\u2013651. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.1032","journal-title":"JAMA Ophthalmol"},{"key":"2465_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/bjo-2024-326480","volume":"110","author":"FF Reichel","year":"2026","unstructured":"Reichel\u00a0FF, Fischer\u00a0MD, Stingl\u00a0K et\u00a0al (2026) Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A-associated retinitis pigmentosa: a\u00a0non-randomised controlled trial. Br J Ophthalmol 110:173\u2013179. https:\/\/doi.org\/10.1136\/bjo-2024-326480","journal-title":"Br J Ophthalmol"},{"key":"2465_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl\u00a0A, Krohne\u00a0TU, Eter\u00a0N et\u00a0al (2018) Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr 172:278\u2013286. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"key":"2465_CR26","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/aos.14852","volume":"100","author":"A Stahl","year":"2022","unstructured":"Stahl\u00a0A, Brunder\u00a0MC, Lagreze\u00a0WA et\u00a0al (2022) Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. Acta Ophthalmol Suppl 100:e91\u2013e99. https:\/\/doi.org\/10.1111\/aos.14852","journal-title":"Acta Ophthalmol"},{"key":"2465_CR27","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl\u00a0A, Lepore\u00a0D, Fielder\u00a0A et\u00a0al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394:1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"2465_CR28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/s41433-023-02919-9","volume":"38","author":"A Stahl","year":"2024","unstructured":"Stahl\u00a0A, Azuma\u00a0N, Wu\u00a0WC et\u00a0al (2024) Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study. Eye 38:1444\u20131453. https:\/\/doi.org\/10.1038\/s41433-023-02919-9","journal-title":"Eye (Lond)"},{"key":"2465_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-025-08850-6","volume":"26","author":"P Knapp","year":"2025","unstructured":"Knapp\u00a0P, Bower\u00a0P, Lidster\u00a0A et\u00a0al (2025) Why do patients take part in research? An updated overview of systematic reviews of psychosocial barriers and facilitators. Trials 26:174. https:\/\/doi.org\/10.1186\/s13063-025-08850-6","journal-title":"Trials"},{"key":"2465_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1033486","volume":"9","author":"C Berkhout","year":"2022","unstructured":"Berkhout\u00a0C, Berbra\u00a0O, Favre\u00a0J et\u00a0al (2022) Defining and evaluating the Hawthorne effect in primary care, a systematic review and meta-analysis. Front Med 9:1033486. https:\/\/doi.org\/10.3389\/fmed.2022.1033486","journal-title":"Front Med (Lausanne)"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02465-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:04:22Z","timestamp":1790816662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02465-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2465"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02465-1","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.\u00a0Seitz, M.\u00a0Ziegler, N.\u00a0Kahle, B.\u00a0Wilhelm und T.\u00a0Peters geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}